Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Ki‐67 and MCM6 labeling indices are correlated with overall survival in anaplastic oligodendroglioma, IDH1‐mutant and 1p/19q‐codeleted: a multicenter study from the French POLA network

Autor: Celso Pouget, Sébastien Hergalant, Emilie Lardenois, Stéphanie Lacomme, Rémi Houlgatte, Catherine Carpentier, Caroline Dehais, Fabien Rech, Luc Taillandier, Marc Sanson, Romain Appay, Carole Colin, Dominique Figarella‐Branger, Shyue‐Fang Battaglia‐Hsu, Guillaume Gauchotte, Christine Desenclos, H. Sevestre, Philippe Menei, A. Rousseau, T. Cruel, S. Lopez, M.I. Mihai, A. Petit, R. Seizeur, I. Quintin‐Roué, C. Adam, F. Parker, S. Eimer, H. Loiseau, L. Bekaert, F. Chapon, D. Ricard, C. Godfraind, T. Khallil, D. Cazals‐Hatem, T. Faillot, C. Gaultier, M. C Tortel, I. Carpiuc, P. Richard, W. Lahiani, H. Aubriot‐Lorton, F. Ghiringhelli, C‐A Maurage, E. Le Rhun, E. M. Gueye, F. Labrousse, F. Ducray, D. Meyronet, O. Chinot, L. Bauchet, V. Rigau, P. Beauchesne, M. Campone, D. Loussouarn, D. Fontaine, F. Vandenbos‐Burel, A. Le. Floch, P. Roger, C. Blechet, M. Fesneau, A. Carpentier, A. Idbaih, J. Y. Delattre, K. Mokhtari, F. Bielle, S. Hamdi, M. Polivka, S. Milin, P. Colin, M. D. Diebold, D. Chiforeanu, E. Vauleon, O. Langlois, A. Laquerriere, F. Forest, M. J. Motso‐Fotso, M. Andraud, G. Runavot, B. Lhermitte, G. Noel, S. Gaillard, C. Villa, N. Desse, C. Rousselot‐Denis, I. Zemmoura, E. Cohen‐Moyal, E. Uro‐Coste, F. Dhermain

Publikováno v: Brain Pathol
Brain Pathology
Brain Pathology, 2020, 30 (3), pp.465-478. ⟨10.1111/bpa.12788⟩
Brain Pathology, Wiley, 2020, 30 (3), pp.465-478. ⟨10.1111/bpa.12788⟩

International audience; Anaplastic oligodendroglioma (AO), IDH‐mutant and 1p/19q codeleted (IDHmut+/1p19qcodel), is a high‐grade glioma with only limited prognostic markers. The primary objective of this study was to evaluate, by immunohistochemi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8810b3c3f3d699dfc454cfd29ae942ea
https://europepmc.org/articles/PMC8018020/

OS9.1 Clinical significance of hypermutation in gliomas

Autor: Karima Mokhtari, Yi Li, Shannon Block, Mehdi Touat, Florence Coulet, A. Idbaih, Alex Duval, Pratiti Bandopadhayay, M. Sanson, Patrick Y. Wen, Antoine F. Carpentier, Marine Giry, J.-Y. Delattre, Franck Bielle, Frédéric Beuvon, Erell Guillerm, Liam F. Spurr, Raymond Y. Huang, Aurélien Marabelle, B Iorglescu, Adam Boynton, Jack Geduldig, Khê Hoang-Xuan, M Lim Fat, Andrew D. Cherniack, Rameen Beroukhim, Keith L. Ligon, Sandro Santagata, Cristina Birzu, David A. Reardon

Publikováno v: Neuro Oncol

BACKGROUND Among patients with glioma, little is known about the clinical significance of hypermutation. We sought to define the determinants of hypermutation in gliomas, and to assess the value of this biomarker for predicting response to standard o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24f5fa6c78ea9c5d54c8075a0bc478be
https://europepmc.org/articles/PMC6795177/

OS11.3 Machine learning for better prognostic stratification and driver genes identification in 1p/19q-codeleted grade III gliomas

Autor: Shai Rosenberg, A. Idbaih, Dominique Figarella-Branger, J.-Y. Delattre, François Ducray, Marie-Laure Tanguy, A. Alentron, A. De Reyneis, Caroline Dehais, Nabila Elarouci

BACKGROUND: Although major advances have been accomplished over the last years in their characterization, 1p/19q-codeleted anaplastic gliomas have variable clinical behavior and mysterious 1p/19q-codeletion “driven” molecular oncogenesis. We have

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3808aae9629fd7c2b9ed2e66cff2cb59
https://europepmc.org/articles/PMC5463688/

OS4.3 Feasibility and benefit of Molecular Profiling to Guide Enrollment of Patients with Recurrent Gliomas in Early Phase Trials

Autor: A Di Stefano, Mehdi Touat, Khê Hoang-Xuan, F. Dhermain, Sarah Dumont, Capucine Baldini, J.-Y. Delattre, A. Idbaih, Jean-Sebastien Frenel, Christophe Massard, Samy Ammari, M Sanson, Nadia Younan, J-C. Soria, Ratislav Bahleda, Franck Bielle, E. Castanon Alvarez, Agusti Alentorn, Antoine Hollebecque

Publikováno v: Neuro Oncol

BACKGROUND Participation of glioma patients in early phase clinical trials has recently shown to be safe, although clinical benefits reported in this population were marginal. We aimed to evaluate whether an enrichment strategy based on molecular pro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83e211f8f3330ec6e5ac1f8c4c7f6ce3
https://doi.org/10.1093/neuonc/noz126.033